Ampio Pharmaceuticals Class Action Lawsuit AMPE | Deadline October 17, 2022
Ampio Pharmaceuticals Class Action Lawsuit (AMPE Lawsuit)
The Gross Law Firm notifies investors that a class action (Ampio Pharmaceuticals Class Action Lawsuit) has commenced in the United States District Court for the District of Colorado on behalf of shareholders of Ampio Pharmaceuticals, Inc. (AMPE) who purchased common stock between December 29, 2020 and August 3, 2022.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:
(i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until October 17, 2022 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
Ampio Pharmaceuticals, Inc. Class Action Lawsuit
Ampio Pharmaceuticals, Inc. Lawsuit
AMPE Class Action Lawsuit
Ampio Pharmaceuticals, Inc. (AMPE) Class Action Lawsuit
Ampio Pharmaceuticals Class Action Lawsuit